PUROLITE (INT.) LTD

Comprehensive Financial Health Assessment: PUROLITE (INT.) LTD

Financial Health Score: B- (Structurally Sound) | N/A (Quantitatively Indeterminate)

Explanation of Score: Without the quantitative "blood work" (filed P&L and Balance Sheet figures), a precise financial health grade is impossible to assign. However, based on the corporate "vitals" we can observe, the company earns a B- for structural and administrative health. The patient is alive, compliant, and well-established, but the minimal share capital suggests it relies heavily on external (likely group) life support for its working capital.

1. Key Vital Signs

• Corporate Pulse (Age & Status): Strong. Incorporated in November 1999, this is a mature entity over 25 years old. Its "Active" status with no flags for liquidation or administration indicates a stable, ongoing heartbeat.
• Compliance Temperature (Filing Health): Healthy. The company’s accounts and confirmation statements are up to date, with the next accounts not due until August 2027. There are no symptoms of administrative fever (overdue filings), which is often an early warning sign of corporate distress.
• Genetic Makeup (Ownership & Control): Interdependent. The company is wholly owned (more than 75% shares) by Purolite Ltd, making it a subsidiary. The presence of multiple directors from the Brodie family, alongside US-based officers, confirms strong parental oversight from an American multinational group.
• Capital Reserves (Share Capital): Frail. With only £2.00 in allotted share capital, the company is "thinly capitalised." This is a common structural setup for group subsidiaries but indicates that the business does not rely on its own equity to fund operations; it requires regular "transfusions" from parent company loans or external credit to function.
• Operational Function (SIC Code): Specialized. Classified under "20590 - Manufacture of other chemical products not elsewhere classified," the company operates in a niche, industrial manufacturing sector which typically requires significant physical assets and working capital.

2. Diagnosis

Diagnosis: Asymptomatic Administration with Unknown Internal Health

From the outside, PUROLITE (INT.) LTD presents as a healthy, compliant, and long-standing entity. The name change in 2012 (from Purolite Global Sales Limited) and the maintenance of a full officer roster suggest a business that has evolved and remains strategically important to its parent group.

However, because the company falls under the umbrella of Purolite Ltd, it suffers from a common subsidiary condition: thin capitalisation. The £2.00 share capital means that the company's actual financial muscle—its ability to pay its own debts if the parent company withdrew support—is entirely hidden within its retained P&L reserves and intercompany loan balances. Without the specific figures for Current Assets, Current Liabilities, and Net Assets, we cannot determine if the company is generating its own healthy cash flow or if it is entirely dependent on the parent company's life support.

3. Prognosis

Prognosis: Stable, but highly correlated to parent group health.

Because the company is tightly integrated into the Purolite corporate structure, its future health is inextricably linked to the wellbeing of Purolite Ltd. As long as the parent group remains financially healthy and willing to support the UK subsidiary, the prognosis is positive. The company’s shift from "Global Sales" to a broader international designation suggests it plays a key role in the group's global strategy. However, if the parent company were to experience financial illness, this subsidiary's minimal equity base would make it highly vulnerable to insolvency, as it lacks an independent financial immune system.

4. Recommendations

To improve financial wellness and ensure long-term viability, the following actions are recommended:

1. Conduct a Full "Blood Panel" (Financial Review): Obtain the full, filed accounts at Companies House to analyze the working capital position (Current Assets vs. Current Liabilities) and the P&L reserve. This will reveal whether the company is self-sustaining or operating at a loss reliant on group bailouts.
2. Monitor Intercompany "Transfusions": Ensure that any loans from the parent company are properly documented and reviewed. While parent loans provide necessary liquidity, if they are suddenly called in or converted to preference shares, it could trigger a sudden cash flow hemorrhage.
3. Evaluate Capital Structure: Consider whether the £2.00 share capital should be increased through a bonus issue funded by retained earnings. This would strengthen the company's equity base, making it more resilient to economic shocks and improving its standalone creditworthiness with external suppliers.